This is a case report of inoperable stage IIIA lung adenocarcinoma with a BRAF V600E mutation, where neoadjuvant targeted therapy with a BRAF inhibitor in combination with a MEK inhibitor was used. After neoadjuvant therapy, the patient underwent radical lung surgery. Postoperative pathology showed a pathological complete response (pCR). The authors report that such combined BRAF+MEK inhibitors are used in advanced or metastatic NSCLC with the BRAF V600E mutation and that perioperative targeted therapy has shown improvement in other mutations (eg, EGFR, ALK). The report underlines that there are only a limited number of published cases for neoadjuvant use in rare mutations such as BRAF V600E. This particular case demonstrates the possibility of achieving pCR in locally advanced NSCLC with BRAF V600E mutation after neoadjuvant treatment with BRAF+MEK inhibitors.